Orexin receptor
hypocretin (orexin) receptor 1 | |
---|---|
Identifiers | |
Symbol | HCRTR1 |
Entrez | 3061 |
HUGO | 4848 |
OMIM | 602392 |
RefSeq | NM_001525 |
UniProt | O43613 |
Other data | |
Locus | Chr. 1 p33 |
hypocretin (orexin) receptor 2 | |
---|---|
Identifiers | |
Symbol | HCRTR2 |
Entrez | 3062 |
HUGO | 4849 |
OMIM | 602393 |
RefSeq | NM_001526 |
UniProt | O43614 |
Other data | |
Locus | Chr. 6 p11-q11 |
Orexin receptor type 2 | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
Symbol | Orexin_rec2 | ||||||||
Pfam | PF03827 | ||||||||
InterPro | IPR004060 | ||||||||
|
The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).[1]
Both orexin receptors exhibit a similar pharmacology - the 2 orexin peptides, orexin-A and orexin-B, bind to both receptors and, in each case, agonist binding results in an increase in intracellular calcium levels. However, orexin-B shows a 10-fold selectivity for orexin receptor type 2, whilst orexin-A is equipotent at both receptors.[2]
Several orexin receptor antagonists are in development for potential use in sleep disorders. Only the crystal structure of OX2 is known.[3]
Selective ligands
Several drugs[4] acting on the orexin system are under development, either orexin agonists for the treatment of conditions such as narcolepsy, or orexin antagonists for insomnia. No non-peptide agonists are yet available, although synthetic Orexin-A polypeptide has been made available as a nasal spray and tested on monkeys. Several non-peptide antagonists are in development however; SB-649,868 by GlaxoSmithKline for sleep disorders is a non-selective orexin receptor antagonist. Another dual orexin antagonist, almorexant (ACT-078573) by Actelion, was abandoned because of side effects. A third entry is Merck's suvorexant (Belsomra),[5] which has recently been approved for use. A new antagonist compound, ACT-462206, was recently studied in humans.[6]
Most ligands acting on the orexin system so far are polypeptides modified from the endogenous agonists Orexin-A and Orexin-B, however there are some subtype-selective non-peptide antagonists available for research purposes.
- SB-334,867 – selective OX1 antagonist
- SB-408,124 – selective OX1 antagonist
- TCS-OX2-29 – selective OX2 antagonist
- EMPA (N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide) – selective OX2 antagonist
- RTIOX-276 – selective OX1 antagonist
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
- Lua error in package.lua at line 80: module 'strict' not found.
- Orexin Receptors at the US National Library of Medicine Medical Subject Headings (MeSH)
<templatestyles src="Asbox/styles.css"></templatestyles>
This article incorporates text from the public domain Pfam and InterPro IPR004060